orphan disease


Also found in: Dictionary, Thesaurus, Legal, Encyclopedia, Wikipedia.

or·phan dis·ease

a disease for which no treatment has been developed because of its rarity (affecting no more than 200,000 persons in the U.S.).
See also: orphan products.

orphan disease

n.
A disease that is relatively rare, for which the development of drugs is considered to be commercially nonviable.

orphan disease

[ôr′fən]
any rare health disorder for which no treatment has been developed. See also orphan drug.
Any disorder affecting less than 200,000 people in the US (less than one per 1,000 people)—regarded by the pharmaceutical industry as too rare for developing commercially viable products

orphan disease

Medtalk A disorder affecting < 200,000 people–US–ie, < 1/1000 people. See NICODARD, NORD.

or·phan dis·ease

(ōr'făn di-zēz')
A disease for which no treatment has been developed because of the disorder's rarity.
See also: orphan products
Mentioned in ?
References in periodicals archive ?
The RODC at The Jackson Laboratory, established in 1929, operates on the mouse model-engineering and acquiring study mice for orphan diseases that have precise patient mutations.
Orphan drugs: rare diseases, rare funding: institutions dedicated to finding treatments for rare diseases employ unique R&D methods
This report provides details of the latest orphan diseases agreements announced in the healthcare sector.
Global Orphan Diseases Partnering 2010-2015: Deal trends, players and financials - New Market Report
Annualized market data for the orphan disease therapeutics in genetic disorders market from 2002-2010 with forecasts to 2018.
Research and Markets: Orphan Disease Therapeutic Disorders to 2018 - Emerging utics in GenAgents in Cystic Fibrosis Offer Strong Opportunities for Investment and Licensing Activity
Patients suffering from orphan diseases can look forward to a wider range of drug options in the future, according to a new report by pharmaceutical market expert GBI Research.
Research and Markets: Orphan Disease Therapeutics Market to 2018 - Big Pharma to Target Orphan Diseases
The report also includes insights into the orphan diseases therapeutics in Oncology Research and Development (R&D) product pipeline and explores the competitive landscape, including major players in the Oncology orphan disease therapeutics market.
Research and Markets: Orphan Diseases Therapeutics in Oncology to 2018 - Strongly Diversified Developmental Pipelines Indicate Long-Term Growth Potential Despite Moderate Scope of Current Late Stage Molecules
The report also includes insights into the orphan diseases therapeutics in CNS Research and Development (R&D) product pipeline and explores the competitive landscape, including major players in the CNS orphan disease therapeutics market.
Research and Markets: Orphan Diseases Therapeutics in CNS to 2017 - Novel Agents such as AMR101 and ACR16 to Provide Treatment Options and Boost the Huntington's Disease Segment
BIO is pleased to recognize the leadership provided by the 2012 Orphan Disease Forum sponsors.
Orphan Diseases and the Future of BioPharma, the Focus of the 2012 Orphan Disease Forum
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced today the opening of the office of the Orphan Disease Treatment Institute Co.
Japan : Orphan Disease Treatment Institute Office Opens inside Daiichi Sankyo Shinagawa R&D Center
Access to the genetic information in the CAG biobank is intended to enable researchers at both firms to work rapidly and efficiently to identify new rare and orphan disease targets and accelerate the development of novel therapies into clinical stage programs.
Medgenics signs research collaboration with The Children's Hospital of Philadelphia
Sarcoidosis is an orphan disease and is diagnosed by the presence of granulomas in the lung, in adults aged between 20 and 40 years.
Araim Pharmaceuticals receives fast track designation for ARA290 from US FDA
GBI Research, the leading business intelligence provider, has released its latest research report entitled: Endpoints-Clinical Trials in Orphan Diseases - Highest Number of Terminated Trials Focused on Mulitiple Myeloma, providing an insight into different endpoints that are used in orphan disease clinical trials.
Research and Markets: Endpoints-Clinical Trials in Orphan Diseases - Highest Number of Terminated Trials Focused on Mulitiple Myeloma
According to the data from the study, the intravitreal injection of recombinant human MANF protein protects both rods and cones from retinal degeneration in an animal model of RP, a degenerative disorder of the eye that affects roughly 100,000 people in the US and qualifies as an orphan disease under FDA guidelines.
Amarantus BioScience Holdings Inc reports encouraging orphan data for MANF in Retinitis Pigmentosa, qualifying as first orphan indication in ophthalmology

Medical browser ?
Full browser ?